A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 662-669

  Vilahur, Gemma ^a   Casani, Laura ^a   Badimon, Lina ^a  

^a CSIC   (Spain)

Author keywords

Aspirin plus clopidogrel; Stents; Thrombosis; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [6 (4 CHLOROPHENYLSULFONYLAMIDO) 2 METHYL 5,6,7,8 TETRAHYDRO 1 NAPHTHYL]PROPIONIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; FIBRINOGEN; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; PROSTAGLANDIN SYNTHASE; S 18886; TETRALIN DERIVATIVE; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 3 ((6 AMINO (4 CHLOROBENZENESULFONYL) 2 METHYL 5,6,7,8 TETRAHYDRONAPHT) 1 YL)PROPIONIC ACID; 3-((6-AMINO-(4-CHLOROBENZENESULFONYL)-2-METHYL-5,6,7,8-TETRAHYDRONAPHT)-1-YL)PROPIONIC ACID; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRIN; FIBRINOLYTIC AGENT; NAPHTHALENE DERIVATIVE; PROPIONIC ACID DERIVATIVE; STAINLESS STEEL; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; EXPERIMENTAL ANIMAL; LOADING DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; AORTA; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; INJURY; METABOLISM; ORAL DRUG ADMINISTRATION; PROSTHESIS; STENT; SWINE; THROMBOCYTE ACTIVATION; THROMBOSIS; TIME;

ADMINISTRATION, ORAL; ANIMALS; AORTA; ASPIRIN; BLEEDING TIME; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMORRHAGE; NAPHTHALENES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROPIONIC ACIDS; PROSTHESIS DESIGN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; STAINLESS STEEL; STENTS; SWINE; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 34548694091     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-04-0272     Document Type: Article

References (43)

1. Schomig A, Kastrati A, Mudra H, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994; 90: 2716-2724.
2. Lau KW, Hung JS, Sigwart U. The current status of stent placement in small coronary arteries < 3.0 mm in diameter. J Invasive Cardiol 2004; 16: 411-416.
3. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Br Med J 1998; 316: 1337-1343.
4. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-1181.
5. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. J Am Med Assoc 2005; 294: 1224-1232.
6. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 348: 1329-1339.
8. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
9. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
10. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
11. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
12. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364-2366.
13. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.
14. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40: 231-237.
15. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S-548S.
16. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938.
17. Gurbel P, Malinin A, Callahan K, et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol 2002; 90: 312-315.
18. Kakkos SK, Nicolaides AN. S-18886 Servier. Curr Opin Investig Drugs 2002; 3: 1324-1327.
19. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-1728.
20. Osende JI, Shimbo D, Fuster V, et al. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004;2:492-498.
21. Maalej N, Osman HE, Shanmuganayagam D, et al. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. J Cardiovasc Pharmacol 2005; 45: 389-395.
22. Gaussem P, Reny JL, Thalamas C, et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005; 3: 1437-1445.
23. Belhassen L, Pelle G, Dubois-Rande JL, et al. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-1204.
24. Verbeuren TJ, Vallez MO, Lavielle G, et al. Activation of thromboxane receptors and the induction of vasomotion in the hamster cheek pouch microcirculation. Br J Pharmacol 1997; 122: 859-866.
25. Rukshin V, Azarbal B, Finkelstein A, et al. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis. J Cardiovasc Pharmacol 2003; 41: 615-624.
26. Badimon L, Turitto V, Rosemark JA, et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-718.
27. Meyer BJ, Badimon JJ, Chesebro JH, et al. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Circulation 1998; 97: 681-685.
28. Badimon L, Badimon JJ, Galvez A, et al. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-320.
29. Merrill E. Rheology of blood. Physiol Rev 1969; 49: 863-888.
30. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-1932.
31. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.
32. Galvez A, Badimon L, Badimon JJ, et al. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost 1986; 56: 128-132.
33. Mertz E. The anomaly of a normal Duke's and a very prolonged saline bleeding time in swine suffering from an inherited bleeding disease. Am J Physiol 1942; 136: 360-362.
34. Moses JW, Leon MB, Popma JJ, et al. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
35. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41: 2093-2099.
36. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
37. Grossmann R, Sokolova O, Schmirr A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
38. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-1910.
39. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYo-cardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-2106.
40. Morawietz H, Breier G. Endothelial cell biology: an update. 5th International Symposium on the Biology of Endothelial Cells. Thromb Haemost 2006; 95: 1025-1030.
41. Penglis PS, Cleland LG, Demasi M, et al. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 2000; 165: 1605-1611.
42. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63: 163-168.
43. Schror K, Weber AA, Hohlfeld T. Clopidogrel "resistance". Thromb Haemost 2004; 92: 229-231.